Cluster immunotherapy in allergic rhinoconjunctivitis. A review on new therapeutic approaches;Die cluster-immuntherapie bei allergischer rhinokonjunktivitis. Eine übersicht über ein neues therapiekonzept

Atemwegs- und Lungenkrankheiten

Volumn 35, Issue 5, 2009, Pages 223-228

  Pfaar, O ^a   Klimek, L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Cluster immunotherapy; Specific immunotherapy

Indexed keywords

ALLERGEN;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ALLERGIC RHINOCONJUNCTIVITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DESENSITIZATION; HUMAN; IMMUNOTHERAPY; PROVOCATION TEST; REVIEW; RHINOCONJUNCTIVITIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 66149164560     PISSN: 03413055     EISSN: None     Source Type: Journal    
DOI: 10.5414/atp35223     Document Type: Review

References (29)

1. Bellinghausen I, Enk AH, Mohamadzadeh M, Lohmann S, Knop J, Saloga J. Epidermal cells enhance interleukin 4 and immunoglobulin E production after stimulation with protein allergen. J Invest Dermatol. 1996; 107: 582-588. (Pubitemid 26338583)
2. Bousquet J, Hejjaoui A, Skassa Brociek W. Double- blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987; 80: 591-598.
3. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular weight allergoid. J Allergy Clin Immunol. 1990; 85: 490-497. (Pubitemid 20075187)
4. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper: Allergen immunotherapy: therapeutic vaccines for allergic deseases. Allergy. 1998; 53: 1-42. (Pubitemid 28346358)
5. Colas C, Monzon S, Venturini M, Lezaun A. Double- blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian Thistle) administered through use of cluster schedule. J Allergy Clin Immunol.2006; 117: 810-816. (Pubitemid 44313815)
6. Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R. Adouble-blind placebo- controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Immunol. 1986; 78: 1180-1184. (Pubitemid 17227465)
7. Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L. Cluster-Immuntherapie bei saisonaler allergischer Rhinitis: Erfahrungen zur Sicherheit einer Inititialtherapie mit Depot- Allergoiden (Purethal®). Laryngo-Rhino-Otologie. 2003; 82: 558-563. (Pubitemid 37055560)
8. Hansen I, Stuck BA, Schneider-Gene S, Mosges R, Klimek L, Hormann K. Cluster-Immuntherapie bei allergischer Rhinokonjunktivitis. Allergologie. 2002; 25: 549-556.
9. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993; 91: 709-722. (Pubitemid 23110716)
10. Horst M, Hejjaoui A, Horst V, Michel F-B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990; 75: 460-472. (Pubitemid 20075183)
11. Iliopoulos O, Proud D, Adkinson NF Jr. Effects of immunotherapy on the early, late, and rechallenge reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol. 1991; 87: 855-866.
12. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol. 1995; 54: 4187-4194.
13. Jutel M, Akdis M, Blaser K, Akdis C. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol. 2005; 5: 365-369.
14. Kesarwala HH, Maccia C, Amaram N, Szep R, Papageorgiu P. Suppressor T cells and soluble suppressor factors in allergy: effect of immunotherapy. Clin Allergy. 1984; 14: 519-524. (Pubitemid 15206756)
15. Klimek L, Reske-Kunz AB, Saloga J. Spezifische Immuntherapie - Hyposensibilisierung. Stuttgart: Thieme; 1999.
16. Klimek L, Wolf H, Mewes T, Dormann D, Reske- Kunz AB, Schnitker J, Mann W. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol. 1999; 103: 47-53. (Pubitemid 29063190)
17. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Bundesgesundheitsbl- Gesundheitsforsch- Gesundheitsschutz. 2001; 44: 709-718.
18. Maasch HJ, Marsh DG. Standardized extracts. modified allergens - allergoids. Clin Rev Allergy. 1987; 5: 89-106.
19. Malling HJ, Weeke B. Position Paper Immunotherapy of the EAACI. Allergy. 1993; 48: 9-35 (and Appendices).
20. Marsh DG, Alexander JF, Norman PS. Boosting of patients with high and low doses of allergoid. JAllergy Clin Immunol. 1982; 69: 99.
21. Mellerup MT, Hahn GW, Poulsen LK, Malling HJ. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000; 30: 1423-1429.
22. Noon L. Prophylactic inoculation of hay fever. Lancet. 1911; 1: 572-573.
23. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol. 1981; 68: 460-470. (Pubitemid 12254024)
24. Norman PS, Marsh DG, Ishizaka K, Lichtenstein LM. New immunologic methods of treatment in IgE-mediated allergies. Allergy and Clinical Immunology. Excerpta Medica, Amsterdam, Oxford: 1977.
25. Serrano P, Algorta J, Martinez A, Gonzales- Quevedo T, Velazquez E. Prospective safety study of immunotherapy administered in a cluster schedule. J Invest Allergol Clin Immunol. 2004; 14: 312-319. (Pubitemid 40378865)
26. Tabar AI, Echechipia S, Blanca EG, Olaguiel JM, Lizaso MT, Gomez B, Akdunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy scheduldes with Dermatophagus pteronyssinus. J Allergy Clin Immunol. 2005; 116: 109-118. (Pubitemid 40909756)
27. Walker SM, Varney VA, Gaga M, Jacobson M, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy. 1995; 50: 405-413.
28. Weber RW, Vaughan TR, Dolen WK. A10-year review of adverse reactions to immunotherapy. J Allergy Clin Immunol. 1988; 81: 295.
29. Zenner HP, Baumgarten C, Rasp G et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol. 1997; 100: 23-29. (Pubitemid 127743101)